Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Serratus Plane Block (SPB) kontra capsaïcine kontra botox-A for kronisk nevropatiske smerter ved post-mastektomisyndrom (SERCABOT)

1. oktober 2026 oppdatert av: Centre Oscar Lambret

Serratus Plane Block (SPB) versus capsaïcine kontra Botox-A for kronisk nevropatiske smerter i post-mastektomisyndrom

The goal of this phase II clinical trial is to study the effectiveness of a treatment with Serratus Plane Block (SPB) or Botox-A in comparison with capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone. The primary outcome will be the pain evaluation at 8 weeks.

123 patients with chronic neuropathic pain of post-mastectomy syndrom insufficiently relieved by systemic treatment alone will be recruited over 24 months at the Centre Oscar Lambret.

Patients will be randomly assigned to one of three treatment groups (41 patients per group):

Capsaicin Botulinum toxin A SPB

Patients will be followed for 24 weeks after the study treatment. The follow-up will include remote evaluation and 2 medical visits during which pain and quality of life will be assessed.

Studieoversikt

Status

Tilbaketrukket

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

SerCaBot is a randomized, open-label, phase II clinical trial designed to evaluate the efficacy of a treatment with Serratus Plane Block (SPB) or Botox-A compared to capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone.

123 patients with will be recruited over 24 months at the Centre Oscar Lambret.

This clinical trial will be proposed to patients with chronic neuropathic pain of post-mastectomy syndrome that is not adequately managed by systemic treatment alone.

After consent, an inclusion assessment will be carried out including clinical examination, anamnesis, pain assessment (questionnaires PCS, NPS, DN4, NPSI and collect of antalgic treatment) and evaluation of quality of life (questionnaire SF12) and depression (questionnaire HADS).

Patients will then be randomly assigned to one of three treatment groups : Capsaicin, Botox-A, SPB (41 patients per group). The randomization will be balanced 1:1:1, controlled by minimisation (with a random factor set at 0.8) for the distribution of the following factors:

  • Pain level at enrolment (continuous NPS)
  • Axillary dissection (yes vs. no)
  • Loco-regional adjuvant radiotherapy (yes vs. no)
  • Prior change of systemic treatment (yes vs. no)

The study treatment will be administered 1 to 2 weeks after randomization. Treatment will be stopped prematurely in the event of unacceptable toxicity or complication. In each group, a repeat of the treatment may be considered after 12 weeks if further pain control is required. In the SPB group, a repeat is also possible every 2 weeks.

Patients will be followed for 24 weeks after the study treatment. Follow-up will include:

  • 2 medical visits at 8 weeks and at 24 weeks including pain assessment (questionnaires NPS, NPSI, record of antalgic treatment), record of adverse events related to study treatment and assessment of quality of life (SF12 questionnaire) and depression (questionnaire HADS).
  • remote assessment at week-1, week-2, week-4 and week-6 including assessment of pain (questionnaires NPS, NPSI, record of antalgic treatment) and record of adverse events. This remote assessment will be repeated in case of repetition of treatment at week 12.

Patients will withdraw from the study after the 24 week medical visit. Early withdrawal will be possible in case of patient's decision of withdrawal, breast surgery during follow-up, or death.

Studietype

Intervensjonell

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Frankrike
    • Hauts-de-France
      • Lille, Hauts-de-France, Frankrike, 59000
        • Centre Oscar Lambret

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria :

  1. Women aged ≥ 18 years;

  2. Unilateral breast cancer treated by total or partial mastectomy:

    • with sentinel lymph node technique (SLN) or axillary dissection;
    • with or without immediate reconstruction using a prosthesis;
    • associated or not with radiotherapy and/or chemotherapy;

  3. Presenting moderate to severe chronic neuropathic pain, defined by:

    • Numerical Pain Scale (NPS) ≥ 3 and DN4 ≥ 4,
    • on a localised aera ((≤ 240 cm²), at the surgical site, in the axillary hollow, or on the inner side of the ipsilateral arm,
    • between 3 and 9 months after breast surgery,
    • with indication of additional locoregional treatment in complement to a systemic treatment of chronic neuropathic pain, as recommended by the SFETD - French Society for the Study and Treatment of Pain (tricyclic antidepressants or IRSNA or gabapentinoid PLUS lidocaine patch, at the appropriate dosage) and implemented for at least 4 weeks;

  4. Patient affiliated with a health insurance plan;

  5. Patient informed and having consented to participate in the trial.

Exclusion Criteria :

  1. Ipsilateral breast cancer recurrence, regardless of the first treatment;

  2. History of breast or thoracic surgery prior to mastectomy with residual pain;

  3. Painful polyneuropathy related to chemotherapy requiring treatment;

  4. Ongoing or planned loco-regional adjuvant radiotherapy within the next 8 weeks;

  5. Treatment area not suitable for potential botulinum toxin type A treatment;

  6. Breast reconstruction using flap or lipomodelling;

  7. Indication for breast reconstruction within the next 8 weeks;

  8. Chronic pain of another etiology such as:

    • Neuropathic pain secondary to a neuroma (localized pain),
    • Radiodermatitis,
    • Phantom breast pain,
    • Lymphedema,
    • Complex regional pain syndrome,
    • Adhesive capsulitis,
    • Fibromyalgia;

  9. Hypersensitivity or allergy to anesthetics, capsaicin, naropein, clonidine hydrochloride, an amide-type local anesthetic, botulinum toxin type A, or any excipient contained in the preparations;

  10. Infection or inflammation at the injection site;

  11. Therapeutic/effective anticoagulation;

  12. Clinical signs or medical history leading to the diagnosis of:

    • Hemostasis disorder,
    • Local infection,
    • Severe renal insufficiency (creatinine clearance < 30 mL/min),
    • Thrombocytopenia < 50,000 platelets/mm3;

  13. Generalized muscle activity disorders (e.g., myasthenia, Lambert-Eaton syndrome);

  14. Heart rate lower than 60/minute;

  15. Severe bradyarrhythmia due to sick sinus syndrome or second or third-degree atrioventricular block;

  16. State of depression (HADS score ≥ 11);

  17. Other contraindication to any of the study treatments;

  18. Inability for the patient to follow the study schedule;

  19. Inability for the patient or the healthcare team to perform the treatment within 2 weeks;

  20. Pregnant or breastfeeding women, women who are able to conceive and who do not use a highly effective method of contraception during the trial and for at least 1 month after the end of treatment ;

  21. Patient under guardianship or curatorship.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Capsaicin 8% Patch (Control)

Participants in this arm will receive an 8% capsaicin patch in a single treatment session in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.
Legemiddel: Capsaicin 8% Patch

One or two capsaicin patch (8%) are applied for 60 minutes to the site of neuropathic pain, in day-hospital. An oral, antalgic pre-medication may be done with one of the following medications (alone or association): paracetamol 1g, nefopam 30 mg, tramadol 100 mg, morphine 10mg, oxycodone 5mg. Capsaicin will be administered in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.

Andre navn:
  • Quutenza®
Eksperimentell: Serratus Plane Block (SPB)

Participants in this arm will undergo a Serratus Plane Block (SPB), a local anesthetic injection administered by a trained anesthesiologist, in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB can be repeated every two weeks up to a maximum of four sessions within the initial 8-week period if pain persists. A repeat treatment may be considered at 12 weeks if further pain control is needed. This intervention aims to provide extended pain relief for neuropathic pain in post-mastectomy patients
Fremgangsmåte: Serratus Plane Block

The Serratus Plane Block (SPB) is a nerve block performed by a trained anesthesiologist to provide localized pain relief. It involves the injection of a local anesthetic: Maximum 150 mg naropeine combined with 150 μg clonidine hydrochloride into the serratus anterior plane under ultrasound guidance. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation.The SBP will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB may be repeated every two weeks up to four times in the initial 8-week period, with an additional repeat at 12 weeks if pain control remains insufficient.

Andre navn:
  • SPB
Eksperimentell: Botulinum Toxin A (Botox-A) Injection

This arm involves administration of Botulinum Toxin A (Botox-A) at the site of pain, in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain remains unresolved, the injection may be repeated at 12 weeks. Botox-A is used here as a local, long-lasting analgesic intervention aimed at reducing chronic neuropathic pain in patients post-mastectomy.
Fremgangsmåte: Botulinum Toxin A

Botulinum Toxin A (Botox-A) is injected into the affected area, with a total of 300 units administered across up to 60 injection sites. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation. This intervention will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks, and is aimed at providing prolonged pain relief for post-mastectomy neuropathic pain. Light sedation is provided, and injections may be repeated at 12 weeks if necessary.

Andre navn:
  • Botox
  • Botox-A

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pain assessment using Numerical Pain Scale (END)
Tidsramme: 8 weeks after treatment initiation, or the closest measurement within +/- 1 week if the 8-week data is missing.

The primary outcome measure is pain assessed by self-evaluation using the Numerical Pain Scale (END) ranging from 0 (no pain) to 10 (worst pain imaginable) at rest, evaluated 8 weeks after treatment (or 9 weeks after randomization if treatment was not performed). The patient's self-assessment reflects individual treatment efficacy. In case of treatment interruption due to immediate intolerance or technical issues, the baseline END will be considered for the primary analysis.
8 weeks after treatment initiation, or the closest measurement within +/- 1 week if the 8-week data is missing.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Success of Pain Control
Tidsramme: Assessed at 8 weeks post-treatment.

Defined as a reduction in pain of 3 points or more on the Numerical Pain Scale (END) at 8 weeks, with failure indicated in other cases.
Assessed at 8 weeks post-treatment.
Evolution of Pain Scores
Tidsramme: Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.

Change in pain levels as self-reported by the patient using the END at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated at 12 weeks).
Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
Neuropathic Component Evaluation
Tidsramme: Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.

Change in neuropathic symptoms assessed via the Neuropathic Pain Symptom Inventory (NPSI) at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated at 12 weeks).
Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
Early Treatment Failure
Tidsramme: Assessed at 7 and 14 days post-treatment

Early failure of local analgesic treatment defined by failure to perform the procedure (due to intolerance or technical issues) or failure to control pain as evaluated at 7 and 14 days post-procedure.
Assessed at 7 and 14 days post-treatment
Modification of introduction of New Analgesic Treatment
Tidsramme: Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.

Documentation of any change in systemic treatement or introduction of new analgesic treatments (e.g., antiepileptics, antidepressants, opioids), with dosages collected at 1, 2, 4, 6, 8, and 24 weeks after treatment (and at 13, 14, 16, and 18 weeks if treatment is repeated).
Assessed at multiple time points: 1, 2, 4, 6, 8, and 24 weeks.
Adverse Events
Tidsramme: From study treatment to 24-weeks follow-up

Monitoring of adverse events possibly related to the treatment (capsaicin, botulinum toxin type A, or SBP block) during and after the local procedure, graded according to NCI-CTCAE v5.0.
From study treatment to 24-weeks follow-up
HADS Scale Evaluation
Tidsramme: Assessed at baseline, 8 weeks, and 24 weeks.

Assessment of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS) at baseline, 8 weeks, and 24 weeks.
Assessed at baseline, 8 weeks, and 24 weeks.
Quality of Life Assessment
Tidsramme: Assessed at baseline, 8 weeks, and 24 weeks.

Evaluation of health-related quality of life using the SF12 scale at baseline, 8 weeks, and 24 weeks.
Assessed at baseline, 8 weeks, and 24 weeks.
Patient General Impression of Change (PGIC)
Tidsramme: Assessed at 8 weeks and 24 weeks

Self-assessment of change in condition from 1 (no change or worse) to 7 (considerable improvement) measured at 8 weeks and 24 weeks.
Assessed at 8 weeks and 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Centre Oscar Lambret

Samarbeidspartnere

Santelys Association
Ligue contre le cancer, France
CTD-CNO, Caen

Etterforskere

  • Hovedetterforsker: Didier DELBROUCK, Anesthesiologist, Centre Oscar Lambret

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. juni 2025

Primær fullføring (Faktiske)

22. september 2026

Studiet fullført (Faktiske)

22. september 2026

Datoer for studieregistrering

Først innsendt

29. januar 2025

Først innsendt som oppfylte QC-kriteriene

29. januar 2025

Først lagt ut (Faktiske)

4. februar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • SERCABOT-2302
  • 2024-517420-20-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere